Shen Lian Biomedical(SH:688098)2022-11-17 14:40Company Overview - Shunlian Bio is a high-tech enterprise specializing in the R&D, production, and sales of veterinary biological products, particularly foot-and-mouth disease (FMD) vaccines [1][2]. - The company holds 7 national new veterinary drug registration certificates, including 2 Class I new veterinary drugs, and has been granted 76 national patents, of which 27 are invention patents [2]. Product and Production Line - The company focuses on a dual-product strategy, with FMD vaccines as the main product and other animal vaccines and veterinary diagnostic reagents as supplementary [2]. - Shunlian Bio has developed a series of high-quality FMD synthetic peptide vaccines, including the first multi-valent synthetic peptide vaccine for pigs [2]. - The company has two production bases in Shanghai and Lanzhou, with production lines for inactivated vaccines and synthetic peptide vaccines that have passed GMP certification [2][3]. Recent Business Performance - In 2021, the company achieved a revenue of CNY 358.43 million, a year-on-year increase of 6.13%, with a compound annual growth rate of 18.83% over the past three years [3]. - The company sold over 3.2 billion doses of FMD vaccine products [3]. - R&D investment in 2021 totaled CNY 68.59 million, accounting for 19.14% of revenue, reflecting a year-on-year increase of 102.94% [3]. New Product Development - The new product "Taijilian," a bivalent inactivated vaccine for FMD, was launched in March 2021 and is expected to significantly enhance market share [3][4]. - The company is also developing several new products, including vaccines for porcine circovirus and swine fever, expected to be launched in the next 1-5 years [5]. Market Strategy and Future Outlook - The company plans to expand its market presence by enhancing sales capabilities and training for distributors, with a focus on large-scale breeding farms [4][5]. - The anticipated recovery of pig prices is expected to boost demand for vaccines, positively impacting the company's sales [4][7]. - The company aims to maintain steady growth while expanding into new vaccine products and markets, ultimately increasing shareholder returns [5][8].